Search Results - "Koya, Richard C."

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction by Moriceau, Gatien, Hugo, Willy, Hong, Aayoung, Shi, Hubing, Kong, Xiangju, Yu, Clarissa C., Koya, Richard C., Samatar, Ahmed A., Khanlou, Negar, Braun, Jonathan, Ruchalski, Kathleen, Seifert, Heike, Larkin, James, Dahlman, Kimberly B., Johnson, Douglas B., Algazi, Alain, Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S.

“…Combined BRAF- and MEK-targeted therapy improves upon BRAF inhibitor (BRAFi) therapy but is still beset by acquired resistance. We show that melanomas acquire…”
Get full text

Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy by MOK, Stephen, KOYA, Richard C, TSUI, Christopher, JINGYING XU, ROBERT, Lidia, WU, Lily, GRAEBER, Thomas G, WEST, Brian L, BOLLAG, Gideon, RIBAS, Antoni

“…Colony stimulating factor 1 (CSF-1) recruits tumor-infiltrating myeloid cells (TIM) that suppress tumor immunity, including M2 macrophages and myeloid-derived…”
Get full text

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy by Shi, Hubing, Hugo, Willy, Kong, Xiangju, Hong, Aayoung, Koya, Richard C, Moriceau, Gatien, Chodon, Thinle, Guo, Rongqing, Johnson, Douglas B, Dahlman, Kimberly B, Kelley, Mark C, Kefford, Richard F, Chmielowski, Bartosz, Glaspy, John A, Sosman, Jeffrey A, van Baren, Nicolas, Long, Georgina V, Ribas, Antoni, Lo, Roger S

“…BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF(V600)-mutant melanoma, but acquired drug resistance is almost universal…”
Get more information

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors by Knight, Deborah A, Ngiow, Shin Foong, Li, Ming, Parmenter, Tiffany, Mok, Stephen, Cass, Ashley, Haynes, Nicole M, Kinross, Kathryn, Yagita, Hideo, Koya, Richard C, Graeber, Thomas G, Ribas, Antoni, McArthur, Grant A, Smyth, Mark J

“…The BRAF mutant, BRAF(V600E), is expressed in nearly half of melanomas, and oral BRAF inhibitors induce substantial tumor regression in patients with…”
Get full text

BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy by KOYA, Richard C, MOK, Stephen, RIBAS, Antoni, OTTE, Nicholas, BLACKETOR, Kevin J, COMIN-ANDUIX, Begonya, TUMEH, Paul C, MINASYAN, Aspram, GRAHAM, Nicholas A, GRAEBER, Thomas G, CHODON, Thinle

“…Combining immunotherapy with targeted therapy blocking oncogenic BRAFV600 may result in improved treatments for advanced melanoma. In this study, we developed…”
Get full text

CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans by RONG RONG HUANG, JALIL, Jason, GLASPY, John A, COCHRAN, Alistair J, RIBAS, Antoni, ECONOMOU, James S, CHMIELOWSKI, Bartosz, KOYA, Richard C, MOK, Stephen, SAZEGAR, Hooman, SEJA, Elizabeth, VILLANUEVA, Arturo, GOMEZ-NAVARRO, Jesus

“…CTLA4 blocking monoclonal antibodies provide durable clinical benefit in a subset of patients with advanced melanoma mediated by intratumoral lymphocytic…”
Get full text

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma by von Euw, Erika, Chodon, Thinle, Attar, Narsis, Jalil, Jason, Koya, Richard C, Comin-Anduix, Begonya, Ribas, Antoni

“…Th17 cells are CD4+ cells that produce interleukin 17 (IL-17) and are potent inducers of tissue inflammation and autoimmunity. We studied the levels of this T…”
Get full text

Human antigen-specific regulatory T cells generated by T cell receptor gene transfer by Brusko, Todd M, Koya, Richard C, Zhu, Shirley, Lee, Michael R, Putnam, Amy L, McClymont, Stephanie A, Nishimura, Michael I, Han, Shuhong, Chang, Lung-Ji, Atkinson, Mark A, Ribas, Antoni, Bluestone, Jeffrey A

“…Therapies directed at augmenting regulatory T cell (Treg) activities in vivo as a systemic treatment for autoimmune disorders and transplantation may be…”
Get full text

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells by Vatakis, Dimitrios N, Koya, Richard C, Nixon, Christopher C, Wei, Liu, Kim, Sohn G, Avancena, Patricia, Bristol, Gregory, Baltimore, David, Kohn, Donald B, Ribas, Antoni, Radu, Caius G, Galic, Zoran, Zack, Jerome A

“…The goal of cancer immunotherapy is the generation of an effective, stable, and self-renewing antitumor T-cell population. One such approach involves the use…”
Get full text

Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer by Liu, Song, Matsuzaki, Junko, Wei, Lei, Tsuji, Takemasa, Battaglia, Sebastiano, Hu, Qiang, Cortes, Eduardo, Wong, Laiping, Yan, Li, Long, Mark, Miliotto, Anthony, Bateman, Nicholas W, Lele, Shashikant B, Chodon, Thinle, Koya, Richard C, Yao, Song, Zhu, Qianqian, Conrads, Thomas P, Wang, Jianmin, Maxwell, George L, Lugade, Amit A, Odunsi, Kunle

“…Efficient identification of neoantigen-specific T-cell responses in epithelial ovarian cancer (EOC) remains a challenge. Existing investigations of spontaneous…”
Get full text

WHSC1/NSD2 regulates immune infiltration in prostate cancer by Want, Muzamil Y, Tsuji, Takemasa, Singh, Prashant K, Thorne, James L, Matsuzaki, Junko, Karasik, Ellen, Gillard, Bryan, Cortes Gomez, Eduardo, Koya, Richard C., Lugade, Amit, Odunsi, Kunle, Battaglia, Sebastiano

“…BackgroundImmunotherapy in prostate cancer (PCa) lags behind the progresses obtained in other cancer types partially because of its limited immune…”
Get full text

Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses by Koya, Richard C., Mok, Stephen, Comin-Anduix, Begoña, Chodon, Thinle, Radu, Caius G., Nishimura, Michael I., Witte, Owen N., Ribas, Antoni

“…A key issue in advancing the use of adoptive cell transfer (ACT) of T cell receptor (TCR) engineered lymphocytes for cancer therapy is demonstrating how TCR…”
Get full text

A rare population of tumor antigen-specific CD4 + CD8 + double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells by Matsuzaki, Junko, Tsuji, Takemasa, Chodon, Thinle, Ryan, Courtney, Koya, Richard C, Odunsi, Kunle

“…High-affinity tumor antigen-specific T-cell receptor (TCR) gene is required to engineer potent T cells for therapeutic treatment of cancer patients. However,…”
Get full text

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines by von Euw, Erika, Atefi, Mohammad, Attar, Narsis, Chu, Connie, Zachariah, Sybil, Burgess, Barry L, Mok, Stephen, Ng, Charles, Wong, Deborah Jl, Chmielowski, Bartosz, Lichter, David I, Koya, Richard C, McCannel, Tara A, Izmailova, Elena, Ribas, Antoni

“…TAK733 is a novel allosteric, non-ATP-binding, inhibitor of the BRAF substrates MEK-1/2. The growth inhibitory effects of TAK733 were assessed in a panel of 27…”
Get full text

Natural killer T cells in advanced melanoma patients treated with tremelimumab by Ibarrondo, F Javier, Yang, Otto O, Chodon, Thinle, Avramis, Earl, Lee, Yohan, Sazegar, Hooman, Jalil, Jason, Chmielowski, Bartosz, Koya, Richard C, Schmid, Ingrid, Gomez-Navarro, Jesus, Jamieson, Beth D, Ribas, Antoni, Comin-Anduix, Begoña

“…A significant barrier to effective immune clearance of cancer is loss of antitumor cytotoxic T cell activity. Antibodies to block pro-apoptotic/downmodulatory…”
Get full text

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors by Knight, Deborah A, Ngiow, Shin Foong, Li, Ming, Parmenter, Tiffany, Mok, Stephen, Cass, Ashley, Haynes, Nicole M, Kinross, Kathryn, Yagita, Hideo, Koya, Richard C, Graeber, Thomas G, Ribas, Antoni, McArthur, Grant A, Smyth, Mark J

Get full text

Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway by Konkankit, Veerauo V, Kim, Won, Koya, Richard C, Eskin, Ascia, Dam, Mai-Anh, Nelson, Stanley, Ribas, Antoni, Liau, Linda M, Prins, Robert M

“…The lack of effective treatments for gliomas makes them a significant health problem and highlights the need for the development of novel and innovative…”
Get full text

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma by Comin-Anduix, Begoña, Sazegar, Hooman, Chodon, Thinle, Matsunaga, Douglas, Jalil, Jason, von Euw, Erika, Escuin-Ordinas, Helena, Balderas, Robert, Chmielowski, Bartosz, Gomez-Navarro, Jesus, Koya, Richard C, Ribas, Antoni

“…The effects on cell signalling networks upon blockade of cytotoxic T lymphocyte-associated antigen-4 (CTLA4) using the monoclonal antibody tremelimumab were…”
Get full text

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma by Hu-Lieskovan, Siwen, Mok, Stephen, Homet Moreno, Blanca, Tsoi, Jennifer, Robert, Lidia, Goedert, Lucas, Pinheiro, Elaine M, Koya, Richard C, Graeber, Thomas G, Comin-Anduix, Begoña, Ribas, Antoni

“…Combining immunotherapy and BRAF targeted therapy may result in improved antitumor activity with the high response rates of targeted therapy and the durability…”
Get more information

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance by Su, Yapeng, Wei, Wei, Robert, Lidia, Xue, Min, Tsoi, Jennifer, Garcia-Diaz, Angel, Moreno, Blanca Homet, Kim, Jungwoo, Ng, Rachel H., Lee, Jihoon W., Koya, Richard C., Comin-Anduix, Begonya, Graeber, Thomas G., Ribas, Antoni, Heath, James R.

“…Continuous BRAF inhibition of BRAF mutant melanomas triggers a series of cell state changes that lead to therapy resistance and escape from immune control…”
Get full text